发明名称 Methods for inducing selective apoptosis
摘要 Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
申请公布号 US9089520(B2) 申请公布日期 2015.07.28
申请号 US201113112739 申请日期 2011.05.20
申请人 Baylor College of Medicine 发明人 Brenner Malcolm K.
分类号 A61K35/17;A61K35/28;A61K35/545;A61K39/00;C12N5/0783;C12N5/0775 主分类号 A61K35/17
代理机构 Grant IP, Inc. 代理人 Grant IP, Inc.
主权项 1. A method of administering transduced or transfected non-allodepleted allogeneic donor T cells to a human patient, comprising a) administering transduced or transfected allogeneic donor T cells to the human patient, wherein: the donor T cells have been transduced or transfected with a nucleic acid comprising (i) a promoter region; and(ii) a polynucleotide that encodes a chimeric protein comprising a multimeric ligand binding region and a caspase-9 polypeptide, wherein the promoter region is operatively linked to the polynucleotide and the multimeric ligand binding region comprises a FKBP12 polypeptide comprising a valine at position 36; and the donor T cells are not allodepleted from the donor cell culture before transfection or transduction; and b) administering a multimeric ligand that binds to the multimeric binding region to the patient, wherein: the patient exhibits graft versus host disease symptoms wherein alloreactive donor T cells are present following a), and the number of alloreactive donor T cells is reduced at least 90% within 24 hours following administration of the multimeric ligand.
地址 Houston TX US